Scilex Holding Company Announces Filing of its Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2024

Core Insights - Scilex Holding Company is focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, and plans to expand into neurodegenerative and cardiometabolic diseases through a joint venture with IPMC Company [1][3][4] Company Overview - Scilex is headquartered in Palo Alto, California and aims to address high unmet needs in pain management with non-opioid therapies [5][3] - The company’s commercial products include ZTlido® for neuropathic pain, ELYXYB® for acute migraine treatment, and Gloperba® for gout flare prophylaxis [3][4] Product Pipeline - Scilex has three product candidates in development: - SP-102 (SEMDEXA™), a viscous gel for epidural injections targeting lumbosacral radicular pain, which has completed Phase 3 studies and received Fast Track status from the FDA [4] - SP-103, a next-generation lidocaine topical system for acute pain, which has recently completed a Phase 2 trial and also received Fast Track status [4] - SP-104, a low-dose naltrexone hydrochloride capsule for fibromyalgia treatment [4] Compliance and Financial Reporting - The company has filed its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, and anticipates regaining compliance with Nasdaq Listing Rule 5250(c)(1) [1][8]